Difelikefalin
FDA-approved peripheral kappa medicines that activate their target pathway for dialysis-associated itch (Korsuva).
What it's for
FDA-approved peripheral kappa medicines that activate their target pathway for dialysis-associated itch (Korsuva).
What it's for
Difelikefalin is a lab-made peptide that selectively activates kappa-opioid receptors (lock-and-key landing spots on cells), designed to act primarily peripherally.
What it does for the body
It treats moderate-to-severe pruritus associated with chronic kidney disease in adults on hemodialysis. It is not a general anti-itch cream substitute for all dermatoses. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
Kappa-opioid receptors (lock-and-key landing spots on cells) activation on peripheral sensory neurons and immune cells can reduce itch signaling. Peripheral selectivity is intended to limit classic central mu-opioid effects.
Research context
Bottom line for readers: Difelikefalin has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Skin research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Difelikefalin — FDA.gov search
- ClinicalTrials.gov search: Difelikefalin — U.S. clinical trials registry
- Drugs@FDA search: Difelikefalin — FDA drug database (if approved)
- PubMed search: Difelikefalin — NCBI PubMed
- PubMed Central search: Difelikefalin — NCBI PMC